title: Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
abstract: OBJECTIVE
  To evaluate the disease control rate (DCR) in heavily pretreated and relapsed ovarian cancer patients re-challenged with a weekly paclitaxel schedule and to establish whether a correlation between dose intensity, progression-free interval (PFI) and overall survival (OS) exists.
  
  
  METHODS
  Retrospective data were collected from 30 heavily pretreated metastatic ovarian cancer patients who received 80 mg/m(2)/week paclitaxel regimen.
  
  
  RESULTS
  The treatment was well tolerated and showed a DCR in 70% of the patients, with only one case of grade 3 hematological toxicity. One patient (3%) showed a complete response, 15 patients (50%) a partial response and five patients (17%) a stabilization of their disease. The regimen was mostly used as a fourth-line chemotherapy (range 2-7). The median dose intensity in responding patients was 57.5 mg/m(2)/week and in those with progressive disease 49.7 mg/m(2)/week. (p = 0.20). PFI and OS were increased in the responder patient groups with a log-rank test of 25.64 (p < 0.001) and 15.10 (p = 0.0001), respectively.
  
  
  CONCLUSIONS
  Weekly administration of paclitaxel was active and well tolerated as a salvage therapy for heavily pretreated ovarian cancer patients.
authors: Department of Oncology, Division of Medical Oncology C, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy.
authors: Gianmaria
authors: G
authors: Miolo
authors: Ettore
authors: E
authors: Bidoli
authors: Davide
authors: D
authors: Lombardi
authors: Davide Adriano
authors: DA
authors: Santeufemia
authors: Giampiero
authors: G
authors: Capobianco
authors: Francesco
authors: F
authors: Dessole
authors: Simona
authors: S
authors: Scalone
authors: Simon
authors: S
authors: Spazzapan
authors: Roberto
authors: R
authors: Sorio
authors: Gianna
authors: G
authors: Tabaro
authors: Andrea
authors: A
authors: Veronesi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel